Thompson Street Capital Partners (TSCP), a private equity firm based in St. Louis, announced today that its portfolio company BioIVT has acquired Santa Clara, California-based Optivia Biotechnology (Optivia), provider of outsourced transporter assay services. Terms of the transaction were not disclosed.
Optivia’s (www.optiviabio.com) assay services include one-of-a-kind multi-vectorial transporter models and predictive modeling of complex molecular transport used in safety testing and pharmaceutical, biotherapeutic and diagnostic product development. The Company offers the world’s largest portfolio of transporter assays, novel multi-transporter models, transformative Transporter System Biology and molecular transport research solutions.
The acquisition of Optivia Biotechnology is another important building block in TSCP’s strategy of leveraging BioIVT’s strong position in hepatocyte and related services to become the leading provider of in-vitro ADME/Tox assays for the pharmaceutical, industrial chemical and cosmetic industries.
